Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of chidamide added to radiotherapy plus chemotherapy for early-stage high-risk extranodal nasal NK/T-cell lymphoma
ChiCTR-IIR-15007350Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tucidinostat in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) (2 arms), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival rate at 2 years. Started Jun 2015; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR-IIR-15007350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-15007350.